Everything below concerns area percent. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-06-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Interpreting chromatographic purity requires attention to detection limits and response factors. Peptides without aromatic residues may absorb weakly at 280 nm, so 214 nm is often preferred, but mobile-phase additives and solvents also absorb at low wavelengths. Co-eluting impurities with different molar absorptivities can produce area percentages that differ from mass percentages. Integration parameters, peak tailing, and baseline choice further affect reported values. For these reasons, method details belong alongside any purity figure, and orthogonal methods are needed to confirm identity and impurity profiles.
Reverse-phase high-performance liquid chromatography is the most common primary method for peptide purity testing. The peptide mixture passes through a hydrophobic stationary phase, and components elute according to differences in hydrophobicity. A mobile phase of water and acetonitrile, often with trifluoroacetic acid as an ion-pairing agent, improves peak shape and retention. Ultraviolet detection at 214 nm records the peptide backbone absorbance, and the main peak area is divided by the total peak area to give an area-percent purity value.
Other chromatographic modes provide complementary information that reverse-phase separation may not capture. Ion-exchange chromatography separates peptides by net charge and can resolve deamidated, oxidized, or truncated variants that co-elute under hydrophobic conditions. Size-exclusion chromatography detects aggregates and higher-order oligomers, which are often invisible in reverse-phase assays. Chiral chromatography can quantify D-amino acid epimers when stereochemical purity matters. Because each mode uses a different separation principle, a single purity number from one method cannot describe all possible impurities.
Chromatographic separation resolves truncated, oxidized, deamidated, and epimerized peptide variants when their retention times differ from the target. Mass spectrometry confirms molecular mass and can reveal modifications that UV detection misses. Liquid chromatography coupled to mass spectrometry combines separation with identity information, which helps distinguish a pure target from a co-eluting impurity. UV-based area percent can overestimate purity if an impurity lacks a chromophore or if the target and impurity have similar response factors. Researchers often report both chromatographic purity and mass confirmation to give a fuller picture.
Additional techniques address components that reversed-phase chromatography may not resolve. Ion-exchange chromatography separates by charge, size-exclusion chromatography detects aggregates, and capillary electrophoresis offers high separation efficiency. Water content is measured by Karl Fischer titration, residual solvents by gas chromatography, and elemental impurities by inductively coupled plasma mass spectrometry. Amino acid analysis or nitrogen determination can estimate peptide content on a mass basis. Purity is frequently reported as area percent, yet standardized comparison across laboratories remains an open question because methods and reporting practices differ.
| Property | Value | Notes |
|---|---|---|
| Typical primary method | Reverse-phase HPLC | Separates mainly by hydrophobicity |
| Typical detection wavelength | 214 nm | Peptide bond absorbance; low UV |
| Common ion-pairing agent | Trifluoroacetic acid | Improves peak shape in acidic mobile phase |
| Typical purity metric | Area percent of main peak | Depends on detection and integration |
| Complementary method | Ion-exchange chromatography | Resolves charge variants |
Orthogonal methods reduce the chance that a single technique misses an impurity. Capillary electrophoresis separates by charge-to-size ratio and can resolve variants that co-elute under one set of HPLC conditions. Amino acid analysis reports composition after hydrolysis and confirms the presence of expected residues. Karl Fischer titration measures water content, while ion chromatography can quantify counterions. No single number captures all aspects of sample quality, so reports often combine several measurements.
Peptide purity testing uses separation methods to estimate the proportion of a sample that corresponds to the target sequence. Reverse-phase high-performance liquid chromatography is the most common technique, separating peptides by hydrophobicity on a nonpolar column. Ultraviolet detection at 214 nm records peptide bonds and aromatic residues. The resulting chromatogram is reported as area percent, which reflects relative absorbance rather than absolute mass. This distinction matters because water, counterions, and residual solvents do not appear in the peptide peak.
Reported purity values can differ between laboratories even for the same sample. Variations arise from column chemistry, mobile-phase composition, gradient slope, detection wavelength, injection load, and integration rules. Area percent also assumes that all species have similar response factors, which is not always true. Method validation examines specificity, linearity, accuracy, precision, limit of detection, and limit of quantitation. When comparing certificates, the method description and representative chromatogram are as important as the headline percentage.
Purity and potency are related but distinct concepts in peptide testing. Purity describes the proportion of the main peptide relative to other detected substances, while potency refers to the biological or functional activity of a defined amount. A highly pure peptide can still have low potency if it is misfolded, aggregated, or chemically modified at a critical residue. Conversely, a less pure preparation may retain high activity if the impurities are inactive. Clear reporting separates these attributes and states the assay used for each.
Cytochrome P450 omega hydroxylases, also termed cytochrome P450 ω-hydroxylases, CYP450 omega hydroxylases, CYP450 ω-hydroxylases, CYP omega hydroxylase, CYP ω-hydroxylases, fatty acid omega hydroxylases, cytochrome P450 monooxygenases, and fatty acid monooxygenases, are a set of cytochrome P450-containing enzymes that catalyze the addition of a hydroxyl residue to a fatty acid substrate. The CYP omega hydroxylases are often referred to as monoxygenases; however, the monooxygenases are CYP450 enzymes that add a hydroxyl group to a wide range of xenobiotic (e.g. drugs, industrial toxins) and naturally occurring endobiotic (e.g. cholesterol) substrates, most of which are not fatty acids. The CYP450 omega hydroxylases are accordingly better viewed as a subset of monooxygenases that have the ability to hydroxylate fatty acids. While once regarded as functioning mainly in the catabolism of dietary fatty acids, the omega oxygenases are now considered critical in the production or break-down of fatty acid-derived mediators which are made by cells and act within their cells of origin as autocrine signaling agents or on nearby cells as paracrine signaling agents to regulate various functions such as blood pressure control and inflammation.
There have been several structures solved for this class of enzymes, given PDB accession codes, and published in peer-reviewed journals. At least 4 such structures have been solved using pig enzymes: PDB: 1OHV, PDB: 1OHW, PDB: 1OHY, PDB: 1SF2, and at least 4 such structures have been solved in Escherichia coli: PDB: 1SFF, PDB: 1SZK, PDB: 1SZS, PDB: 1SZU. There are actually some differences between the enzyme structure for these organisms. E. coli enzymes of GABA-T lack an iron-sulfur cluster that is found in the pig model. Amino acid residues found in the active site of 4-aminobutyrate transaminase include Lys-329, which are found on each of the two subunits of the enzyme. This site will also bind with a pyridoxal 5'- phosphate co-enzyme. Aminooxyacetic acid Gabaculine Phenelzine Phenylethylidenehydrazine (PEH) Rosmarinic acid Valproic acid Vigabatrin 4-Aminobutyrate+Transaminase at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Pearl PL, Parviz M, Hodgeman R, Gibson KM, Reimschisel T (2015). "GABA-transaminase deficiency". MedLink Neurology.
In May 1952, Raymond Gosling, a graduate student working under the supervision of Rosalind Franklin, took an X-ray diffraction image, labeled as "Photo 51", at high hydration levels of DNA. This photo was given to Watson and Crick by Maurice Wilkins and was critical to their obtaining the correct structure of DNA. Franklin told Crick and Watson that the backbones had to be on the outside. Before then, Linus Pauling, and Watson and Crick, had erroneous models with the chains inside and the bases pointing outwards. Franklin's identification of the space group for DNA crystals proved her correct. In February 1953, Linus Pauling and Robert Corey proposed a model for nucleic acids containing three intertwined chains, with the phosphates near the axis, and the bases on the outside. Watson and Crick completed their model, which is now accepted as the first correct model of the double helix of DNA. On 28 February 1953 Crick interrupted patrons' lunchtime at The Eagle pub in Cambridge, England to announce that he and Watson had "discovered the secret of life".
Afucosylated monoclonal antibodies are monoclonal antibodies engineered so that the oligosaccharides in the Fc region of the antibody do not have any fucose sugar units. When antibodies are afucosylated, antibody-dependent cellular cytotoxicity (ADCC) is increased. Most approved monoclonal antibodies are of the IgG1 isotype, where two N-linked biantennary complex-type oligosaccharides are bound to the Fc region. The Fc region exercises the effector function of ADCC through its interaction with leukocyte receptors of the FcγR family. ADCC is important in the efficacy of cancer antibodies, but with many approved cancer antibodies there is less ADCC than could be desired due to nonspecific IgG competing with the drugs for binding to FcγIIIa on natural killer cells. Afucosylated monoclonal antibodies overcome this problem through improved FcγIIIa binding.
Sources: en.wikipedia.org
DHFR has been used as a tool to detect protein–protein interactions in a protein-fragment complementation assay (PCA), using a split-protein approach. DHFR-lacking CHO cells are the most commonly used cell line for the production of recombinant proteins. These cells are transfected with a plasmid carrying the dhfr gene and the gene for the recombinant protein in a single expression system, and then subjected to selective conditions in thymidine-lacking medium. Only the cells with the exogenous DHFR gene along with the gene of interest survive. Supplementation of this medium with methotrexate, a competitive inhibitor of DHFR, can further select for those cells expressing the highest levels of DHFR, and thus, select for the top recombinant protein producers. Dihydrofolate reductase has been shown to interact with GroEL and Mdm2. Click on genes, proteins and metabolites below to link to respective articles.
Analysis of Sulfolobus solfataricus CRISPRs revealed further complexities to the canonical model of spacer insertion, as one of its six CRISPR loci inserted new spacers randomly throughout its CRISPR array, as opposed to inserting closest to the leader sequence. Multiple CRISPRs contain many spacers to the same phage. The mechanism that causes this phenomenon was discovered in the type I-E system of E. coli. A significant enhancement in spacer acquisition was detected where spacers already target the phage, even mismatches to the protospacer. This 'priming' requires the Cas proteins involved in both acquisition and interference to interact with each other. Newly acquired spacers that result from the priming mechanism are always found on the same strand as the priming spacer. This observation led to the hypothesis that the acquisition machinery slides along the foreign DNA after priming to find a new protospacer.
Take breast cancer as an example. The sensitivity of traditional ultrasound screening for breast cancer can be 76%. While with the blood-based mRNA diagnostic method, the sensitivity could be 80.6%. mRNA-based disease diagnostic technologies allow quantitive measurement of mRNA in the certain samples, such as leukemia As some technologies such as RNA-seq can provide the entire transcriptome of individual, the mRNA-based disease diagnosis can be developed in the landscape of personalized medicine. In HER-2 breast cancer, detection of ERBB2 mRNA expression levels is helpful in predicting response to anti-HER2-based treatments. As mentioned above, the mRNA-based disease diagnostic technology is more sensitive and specific to certain diseases. Even though there is no obvious symptom, the mRNA-based disease diagnostic technology can serve as screening method for early changes in RNA levels. High serum metadherin mRNA expression was observed in colorectal cancer and associated with poorly differentiated histological grades
Chemistry... Key to Better Living. Diamond Jubilee Volume: A Record of Chemical Progress During the First 75 Years of the American Chemical Society. American Chemical Society. 1951. Skolnik, Herman; Reese, Kenneth M., eds. (1976). A Century of chemistry: the role of chemists and the American Chemical Society. Washington, D.C.: American Chemical Society. ISBN 978-0841203075. J. J. Bohning 2001. American Chemical Society Founded 1876. ACS, Washington, D.C. Reese, Kenneth M., ed. (2002). The American Chemical Society at 125: A recent history 1976–2001. American Chemical Society. ISBN 978-0-8412-3851-0. ACS website ACS Publications website ACS Chemical & Engineering News ACS Chemical Abstracts Service (CAS) International Year of Chemistry 2011(archived) A Cauldron Bubbles: PubChem and the American Chemical Society — Information Today, June 2005 ACS Chemical Biology WIKI(archived) ACS Chemical Biology Community(archived) ACS Green Chemistry Institute ACS Organic Division Leete Award Gassman Award
With an increasing population, the production of food needs to increase with it. It is estimated that a 70% increase in food production is needed by 2050 in order to meet the Declaration of the World Summit on Food Security. But with the degradation of agricultural land, simply planting more crops is no longer a viable option. New varieties of plants can in some cases be developed through plant breeding that generate an increase of yield without relying on an increase in land area. An example of this can be seen in Asia, where food production per capita has increased twofold. This has been achieved through not only the use of fertilisers, but through the use of better crops that have been specifically designed for the area.
Sources: en.wikipedia.org
HPLC purity measures the relative area of the main peptide peak compared with all detected peaks under one set of separation and detection conditions. It is an operational value rather than an absolute mass fraction. Compounds that do not absorb at the detection wavelength or that co-elute with the main peak are not counted.
The peptide bond absorbs ultraviolet light near 214 nm, so this wavelength detects the backbone of most peptides regardless of aromatic content. It is more universal than 280 nm, which mainly detects tryptophan, tyrosine, and phenylalanine. Mobile-phase components can also absorb at 214 nm, so blank subtraction and method controls are important.
No single chromatographic method resolves all possible peptide impurities, because variants may differ in charge, size, hydrophobicity, or stereochemistry. Deamidated and oxidized forms may co-elute in reverse-phase systems, while aggregates require size-exclusion separation. Orthogonal methods and mass spectrometry are therefore used together for a fuller impurity profile.
It usually refers to the relative peak area of the target peptide in a chromatogram, not the mass fraction of the entire sample. Different analytical methods can yield different purity values. Water, counterions, and residual solvents are excluded unless the calculation specifies otherwise.